BioAge Labs, Inc (BIOA) - Net Assets
Based on the latest financial reports, BioAge Labs, Inc (BIOA) has net assets worth $374.91 Million USD as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($396.93 Million) and total liabilities ($22.02 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check how strategically is BioAge Labs, Inc's equity deployed to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $374.91 Million |
| % of Total Assets | 94.45% |
| Annual Growth Rate | 12.67% |
| 5-Year Change | 1144.93% |
| 10-Year Change | N/A |
| Growth Volatility | 222.71 |
BioAge Labs, Inc - Net Assets Trend (2013–2025)
This chart illustrates how BioAge Labs, Inc's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see BioAge Labs, Inc market cap and net worth.
Annual Net Assets for BioAge Labs, Inc (2013–2025)
The table below shows the annual net assets of BioAge Labs, Inc from 2013 to 2025. Also explore BioAge Labs, Inc (BIOA) net asset momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $272.05 Million | -15.81% |
| 2024-12-31 | $323.13 Million | +286.35% |
| 2023-12-31 | $-173.40 Million | -54.05% |
| 2022-12-31 | $-112.56 Million | -615.08% |
| 2017-12-31 | $21.85 Million | -54.93% |
| 2016-12-31 | $48.49 Million | +4.61% |
| 2015-12-31 | $46.36 Million | -19.42% |
| 2014-12-31 | $57.53 Million | -11.50% |
| 2013-12-31 | $65.01 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to BioAge Labs, Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 21837205000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Comprehensive Income | $278.00K | 0.10% |
| Other Components | $605.19 Million | 222.45% |
| Total Equity | $272.05 Million | 100.00% |
BioAge Labs, Inc Competitors by Market Cap
The table below lists competitors of BioAge Labs, Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Waterstone Financial Inc
NASDAQ:WSBF
|
$371.41 Million |
|
Anhui Xinbo Aluminum Co Ltd
SHE:003038
|
$371.53 Million |
|
Open Lending Corp
NASDAQ:LPRO
|
$371.53 Million |
|
RDC Semiconductor Co Ltd
TWO:3228
|
$371.70 Million |
|
Zhejiang Hengwei Battery Co. Ltd.
SHE:301222
|
$371.26 Million |
|
Kairuide Holding Co Ltd
SHE:002072
|
$371.24 Million |
|
JTL Industries Ltd
NSE:JTLIND
|
$371.20 Million |
|
Fine Semitech Corp
KQ:036810
|
$371.17 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in BioAge Labs, Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 323,127,000 to 272,051,000, a change of -51,076,000 (-15.8%).
- Net loss of 80,605,000 reduced equity.
- New share issuances of 17,155,000 increased equity.
- Other comprehensive income increased equity by 33,000.
- Other factors increased equity by 12,341,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-80.61 Million | -29.63% |
| Share Issuances | $17.16 Million | +6.31% |
| Other Comprehensive Income | $33.00K | +0.01% |
| Other Changes | $12.34 Million | +4.54% |
| Total Change | $- | -15.81% |
Book Value vs Market Value Analysis
This analysis compares BioAge Labs, Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 3.51x to 1.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $2.31 | $8.09 | x |
| 2014-12-31 | $2.04 | $8.09 | x |
| 2015-12-31 | $1.64 | $8.09 | x |
| 2016-12-31 | $1.42 | $8.09 | x |
| 2017-12-31 | $0.52 | $8.09 | x |
| 2022-12-31 | $-3.29 | $8.09 | x |
| 2023-12-31 | $-5.07 | $8.09 | x |
| 2024-12-31 | $9.01 | $8.09 | x |
| 2025-12-31 | $7.57 | $8.09 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently BioAge Labs, Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -29.63%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -896.11%
- • Asset Turnover: 0.03x
- • Equity Multiplier: 1.08x
- Recent ROE (-29.63%) is above the historical average (-84.36%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -51.10% | -1246.33% | 0.02x | 1.75x | $-39.72 Million |
| 2014 | -80.69% | -3008.45% | 0.01x | 2.65x | $-52.17 Million |
| 2015 | -80.31% | -1713.94% | 0.02x | 3.09x | $-41.86 Million |
| 2016 | -46.36% | -271.72% | 0.05x | 3.33x | $-27.33 Million |
| 2017 | -449.15% | -656.84% | 0.21x | 3.18x | $-100.34 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-28.47 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-46.51 Million |
| 2024 | -22.01% | 0.00% | 0.00x | 1.11x | $-103.42 Million |
| 2025 | -29.63% | -896.11% | 0.03x | 1.08x | $-107.81 Million |
Industry Comparison
This section compares BioAge Labs, Inc's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $180,509,986
- Average return on equity (ROE) among peers: -187.74%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| BioAge Labs, Inc (BIOA) | $374.91 Million | -51.10% | 0.06x | $371.31 Million |
| Aurora Cannabis Inc (ACB) | $219.71 Million | -5.90% | 0.47x | $236.15 Million |
| ADC Therapeutics SA (ADCT) | $-185.83 Million | 0.00% | 0.00x | $134.82 Million |
| Akanda Corp (AKAN) | $-5.03 Million | 0.00% | 0.00x | $1.51 Million |
| Akebia Ther (AKBA) | $5.23 Million | -1801.64% | 67.08x | $239.89 Million |
| Alkermes Plc (ALKS) | $853.85 Million | 2.93% | 0.68x | $7.84 Billion |
| Amylyx Pharmaceuticals Inc (AMLX) | $-151.17 Million | 0.00% | 0.00x | $3.58 Billion |
| Amphastar P (AMPH) | $281.86 Million | -3.80% | 0.38x | $980.07 Million |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $346.79 Million | -104.36% | 9.57x | $5.96 Billion |
| Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) | $344.93 Million | 26.40% | 10.61x | $3.57 Billion |
| Anika Therapeutics Inc (ANIK) | $94.76 Million | 8.93% | 0.40x | $279.44 Million |
About BioAge Labs, Inc
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhib… Read more